Should you wait, book a visit, or get care now?

Which warning signs can't wait?

After a fall, trouble putting weight on the joint or a bent-looking joint calls for prompt care. A joint that suddenly gives way also needs an exam.

New numbness, weakness, or loss of bladder or bowel control with back soreness is urgent. After treatment, get fast care for fever, spreading redness, or soreness that keeps climbing.

Calf swelling and redness after care can mean a blood clot. Don't spend that time testing another home remedy.

When can I give home care more time?

A mild ache that settles with rest and easy motion can often be watched. Note any swelling, lost sleep, shorter walks, and how long worse days last.

Keep doing the exercises your doctor or physical therapist chose for you. They may need to change as your strength returns.

Still, you don't have to repeat care that isn't helping. Make an appointment if the ache stays, worsens, or limits ordinary tasks.

What should happen at that exam?

At the exam, you'll explain when the ache began and which movements make it better or worse. The person examining you checks strength, motion, heat, swelling, and sore spots.

An X-ray can help when it may change the next choice. It can't decide your care without the exam and your daily limits.

Bring your medicine list and any old reports that are easy to find. Leave knowing the choices, risks, costs, and next step.

Sources

1. The OARSI non-surgical management guideline evaluated 60 interventions with GRADE methodology and built its recommendations around core treatments - structured exercise, weight management and self-management education - for every patient with knee osteoarthritis, regardless of what else is added.

   Bannuru RR, et al. — OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage, 2019. DOI: 10.1016/j.joca.2019.06.011.

2. A systematic review of 21 studies re-examining the familiar '20 percent are dissatisfied after knee replacement' figure found the actual average dissatisfaction rate was 10 percent, and 7.3 percent when complications were excluded - the surgical benchmark a cash-pay injection is implicitly competing against.

   DeFrance MJ, et al. — Are 20% of Patients Actually Dissatisfied Following Total Knee Arthroplasty? A Systematic Review of the Literature. J Arthroplasty, 2023. DOI: 10.1016/j.arth.2022.10.011.

3. The AAOS Surgical Management of Osteoarthritis of the Knee clinical practice guideline sets out 16 recommendations and seven options for surgical management based on a systematic review of the published evidence - the reference point for when a joint has moved past the injectable tier.

   Srivastava AK, et al. — American Academy of Orthopaedic Surgeons Clinical Practice Guideline Summary of Surgical Management of Osteoarthritis of the Knee. J Am Acad Orthop Surg, 2023. DOI: 10.5435/JAAOS-D-23-00338.

4. A retrospective comparison of 523 bone marrow aspiration procedures against 435 open iliac crest bone graft harvests found aspiration significantly reduced complications - relevant because marrow aspiration for a joint injection is a real procedure with a real, if low, complication rate.

   Hernigou P, et al. — Morbidity of graft harvesting versus bone marrow aspiration in cell regenerative therapy. Int Orthop, 2014. DOI: 10.1007/s00264-014-2318-x.

5. FDA states in its consumer alert that the only FDA-approved stem cell products in the United States are blood-forming stem cells derived from umbilical cord blood, approved for disorders of the blood-forming system, and that NONE of these products - stem cells, stromal vascular fraction, umbilical cord blood, Wharton's jelly or amniotic fluid - has been approved for the treatment of any orthopedic condition, including osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain or shoulder pain.

   US Food and Drug Administration, Center for Biologics Evaluation and Research — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. , 2020.